Risk Factors Associated with Early Progression After 177 Lu-DOTATATE in Patients with Advanced/ Metastatic Neuroendocrine Tumours (EANM 2026) - Sep 29, 2026 - Abstract #EP-0870; "Bone involvement, unknown primary tumour origin, and a high baseline total tumour burden (TLSRE) may serve as potential predictors of early progression after 177Lu-DOTATATE. These findings suggest that patients presenting with these risk factors may benefit from stringent post-PRRT surveillance or intensified treatment protocols."
Clinical • Metastases • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR
|
|
D. Maccora 1; S. Rea 1; A. Annovazzi 1; G. Iaccarino 2; A. Soriani 2; R. Sciuto 1
|